Search

The Canadian Society for Immunology (CSI) established a formal Equity, Diversity, and Inclusion (EDI) Committee with the goal of providing EDI advocacy and leadership within the CSI, as well as in the broader scientific community. A first task of this committee was to review the publicly available historical data on gender representation within the CSI's membership, leadership, award recipients, and conference chairs/presenters as a step in establishing a baseline reference point and monitoring the trajectory of future success in achieving true inclusion. We found that, except for overall membership and a specific subset of awards, all categories showed a historical bias toward men, particularly prior to 2010. Bias persists in various categories, evident even in recent years. However, we note an encouraging trend toward greater gender parity, particularly in the roles of President, symposium presenters, and workshop chairs, especially from 2017 onward. We present these findings as well as our recommendations to enhance inclusivity. These include a more comprehensive collection and secure storage of self-identification data, emphasis on EDI as an essential component of all annual meeting activities, and innovative measures of outreach, collaboration, and leadership with the aim of making the CSI a model for improving EDI in other professional research societies., (Copyright © 2024 by The American Association of Immunologists, Inc.)

Objective: To study the functional outcome of patients undergoing transurethral enucleation and resection of the prostate (TUERP) vs patients undergoing holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction., Materials and Methods: We retrospectively analyzed our prospectively collected database of two groups of patients. Twenty-four patients underwent TUERP (group 1), and 27 underwent HoLEP (group 2). Preoperative characteristics, intervention parameters, postoperative functional outcomes, uroflowmetry, and complications were collected., Results: Mean prostate size in groups 1 and 2 were 87.2 and 93.5 cc, respectively. The mean duration of surgery was 110 minutes in group 1 and 136 minutes in group 2. In group 1, prostate-specific antigen (PSA) dropped from 4.4 to 1.2 ng/cc after 12 months. International Prostate Symptom Score (IPSS) was 3.75 at 12 months with a preoperative value of 20.9. With respect to maximum urinary flow rate (Q max ), it increased to 21.8 mL/s from a preoperative value of 6.4 mL/s. In group 2, the PSA dropped from 7.6 to 1.3 ng/cc. IPSS dropped from 22.3 to 3.8, Q max increased from 7.7 to 22.5 mL/s. Hemoglobin, complications, and all studied parameters were not statistically significant between both groups., Conclusion: In this study, TUERP was safe and efficacious in benign prostatic hyperplasia patients with large glands. Modifications can be implemented on the standard transurethral resection of the prostate technique to treat patients with prostate sizes >70 cc.

Background: Previously all subarachnoid hemorrhage (SAH) patients were admitted, whereas now patients with angiography may be discharged., Objective: To survey neurosurgeons to determine current practice and what constitutes a clinically significant subarachnoid hemorrhage., Methods: We surveyed all neurosurgeons listed in the Canadian Medical Directory. We used a modified Dillman technique with up to five mailed surveys plus a pre-notification letter. Neurosurgeons rated the significance of 13 scenarios of subarachnoid hemorrhage. Scenarios varied from aneurysmal subarachnoid hemorrhage to patients with isolated xanthochromia in cerebrospinal fluid. Each scenario was rated for clinical significance using a 5-point scale [1(always) to 5(never)]., Results: Of the 224 surveyed, 115 neurosurgeons responded. Scenarios with aneurysms requiring intervention, arteriovenous malformations, death or any surgical intervention all had median responses of 1 (IQR 1, 1). Scenarios having xanthochromia and few red blood cells in cerebrospinal fluid with negative computerized tomogram (CT) and angiography had median responses of 3 (IQR 1, 4). Scenarios with perimesencephalic pattern on CT with negative angiography had median of 3 (IQR 2, 4). Scenarios where patient is discharged from the emergency department had median of 4 (IQR 3, 5)., Conclusion: Subarachnoid hemorrhages due to aneurysms or arteriovenous malformations causing death or requiring surgical intervention are always clinically significant. Other types of nonaneurysmal subarachnoid hemorrhages had inconsistent ratings for clinical significance. These survey results highlight the need for further discussions to standardize the diagnosis of what constitutes a clinically significant subarachnoid hemorrhage and what care should be afforded to these patients.

Background and Purpose: Four percent to 10% of patients with transient ischemic attack (TIA) have a stroke or die within 1 week of their diagnosis. This national survey examined Canadian neurologists' current practice for managing TIA, the need for a clinical decision rule to identify high-risk patients, and the required sensitivity of such a rule., Methods: We surveyed 650 neurologists registered in a national physician directory. We used a modified Dillman technique with a prenotification letter and up to 5 survey attempts using a mailed letter. Neurologists were asked 33 questions about demographics, current management of adult patients with TIA, if a clinical decision rule is required to identify high-risk patients with TIA for impending stroke/death, and the required sensitivity of this rule., Results: We had a response rate of 49.8% (324 of 650). Respondents were 78.3% male and had a mean age of 50.3 years. Of respondents, 49.2% (95% CI: 45.3% to 53.1%) reported using an existing clinical tool to risk-stratify patients. Overall, 95.0% (95% CI: 93.3% to 96.7%) reported they would consider using a sensitive, validated clinical decision rule for risk-stratifying patients with TIA. The median required sensitivity of a rule was 92% (interquartile range, 90 to 95)., Conclusions: We found that Canadian neurologists would use a highly sensitive clinical decision rule to risk-stratify patients with TIA. The median required sensitivity of 92% is higher than the high risk category of any existing tool. Our results indicate a clinical decision rule to predict high-risk TIA needs to be more sensitive than the currently available rules.